LEXINGTON, Mass., June 24, 2013 (GLOBE NEWSWIRE) -- In response to a recent national survey finding that three-quarters of Americans don't fully understand the role that iron plays in the body,1 AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced the launch of Iron Matters™, a new campaign to help patients better understand the causes and impact of iron deficiency anemia (IDA). More than 4 million Americans have IDA, yet few understand the condition and limited educational resources exist on IDA, its underlying causes and the overall importance of iron's role in maintaining good health.
"Iron Matters offers patients and their caregivers a trustworthy resource for information on iron deficiency anemia (IDA) and the importance of maintaining healthy iron levels," said Cheryl Garrison, co-founder and executive director of the Iron Disorders Institute, a non-profit dedicated to informing the public about iron disorders. "We see firsthand the deep impact IDA can have on patients' daily lives and know that a well-informed patient is vital in today's health care environment. We welcome Iron Matters to the great challenge of changing attitudes of complacency around this often-ignored condition."
According to results from a May 2013 online survey, most adults recognize the important role of iron in the production of healthy red blood cells.2 Nevertheless, IDA is often ignored, forcing patients to tolerate the chronic symptoms of anemia, including extreme fatigue, dizziness and irritability, among others. Moreover, many young women of child-bearing age, for whom iron is particularly critical, have little understanding of the role of iron in their health.3
The underlying causes of IDA are diverse and can impact many different people, although the majority of those diagnosed with IDA are women. Over one and a half million IDA patients are estimated to have chronic kidney disease, while another 2.4 million suffer from anemia due to other causes such as abnormal uterine bleeding, gastrointestinal disorders, inflammatory diseases and chemotherapy-induced anemia.4
AMAG's Iron Matters campaign will help patients and health care providers better understand and identify the symptoms and causes of IDA through a variety of educational resources and outreach activities, including:
- First-of-its kind, patient-focused online information portal about IDA and the importance of iron
- Regularly updated expert columns on various aspects of IDA, such as simple ways to boost your iron levels through diet and iron-rich recipes, written by leaders in nutrition, women's health, hematology and oncology and gastrointestinal conditions that lead to IDA
- Compelling firsthand accounts of how real patients came to learn they had IDA and were able to overcome debilitating symptoms of the condition, in partnership with their health care providers
- Tip sheets and frequently asked questions (FAQ) that health care providers can share directly with patients or that patients can download and print from the website
- Educational opportunities for health care providers from fields most likely to come into contact with IDA, including gastroenterology, hematology/oncology and nephrology
- Outreach and collaboration with third-party advocacy and medical groups whose missions are to arm patients, providers and caregivers with the latest scientific knowledge on relevant health conditions
- Direct communication with medical and consumer media to help get the word out about resources available on IDA
"We know that iron deficiency anemia is a serious health problem, yet many patients continue to suffer needlessly," said William Heiden, president and chief executive officer of AMAG. "Our goal with the Iron Matters campaign is to help enable patients and health care providers to more easily recognize the effects and causes of IDA. We also hope Iron Matters will open an important dialogue between patients and their health care providers."
More information on the Iron Matters campaign can be found on the official website, www.ironmatters.com.
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) is a specialty pharmaceutical company with a focus on anemia in the United States. For additional company information, please visit www.amagpharma.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein which do not describe historical facts, including but not limited to statements regarding: our goal to help patients and health care providers more easily recognize the effects and causes of IDA; and that Iron Matters will open an important dialogue between patients and health care providers, are forward-looking statements which involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements.
The risks and uncertainties associated with our business are identified in our Securities and Exchange Commission filings, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2012 and subsequent filings with the SEC. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made.
We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
AMAG Pharmaceuticals is registered trademark and Iron Matters is a trademark of AMAG Pharmaceuticals, Inc.
1 The Perceptions of Iron Poll was sponsored by AMAG Pharmaceuticals and conducted by APCO Insight among 908 adults aged 18-55 in the United States, from May 28-31, 2013, using Research Now's OmniPulse®, an online omnibus survey provider. The survey has a sampling error of ±3.3 percentage points at the 95% confidence interval. Sample frame was based on demographic information from the U.S. Census Bureau and data have not been weighted.
2 Perceptions of Iron Poll, Research Now's OmniPulse®, May 2013.
4 U.S. Census; U.S. Renal Data System, USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2010: 41-42; Fishbane, S. et al. Iron Indices in CKD in the NHANES 1998-2004. Clin J Am Soc Nephrol. 2009 January; 4(1): 57–61.
CONTACT: AMAG Pharmaceuticals, Inc. Contact Amy Sullivan, 617-498-3303Source:AMAG Pharmaceuticals, Inc.